The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial ...
With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...
The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...
In recent health developments, the FDA approved a new drug by BridgeBio for a deadly heart condition. Additionally, Merck's ...
Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.
Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to significantly improve motor function in a late-stage trial, sending the shares of rival Scholar Rock, ...
In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
(In Nov. 22 story, corrects list price of Pfizer's drug to about $268,000 from $225,000 in paragraph 3) (Reuters) -The U.S.
Citi analyst David Lebowitz keeps a Buy rating on BridgeBio (BBIO) with a $45 price target after the FDA granted approval for Attruby for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback